Home / About us / Leadership / Pia Elustondo, PhD
Pia Elustondo, PhD
Senior Director of Research
Dr. Elustondo received her Bachelor of Science in Biochemistry and Clinical Diagnosis from the University of Buenos Aires, and her Ph.D. in Medicine from the Memorial University of Newfoundland.
Before joining AGADA, she worked for the Dalhousie University Department of Physiology and Biophysics as a post-doc, studying mitochondrial physiology and mechanisms of cell death.
As Senior Research Director, Pia guides the scientific direction of AGADA’s research programs with a focus on rigorous study design and methodology, working closely with multidisciplinary teams to ensure projects yield reliable, high-quality data. Pia also collaborates with the business development and marketing teams to translate AGADA’s laboratory and research capabilities into practical solutions that meet client needs and support organisational growth.
Get in touch
To learn how AGADA Biosciences could support your program, get in touch with our team and start the conversation.
How we work
We bring an agile, collaborative and responsive approach to every engagement, shaping our support around the needs of your program rather than a rigid process. Whether you engage us at a single stage or across multiple points in development, we work to de-risk programs, protect data integrity and help your teams progress with confidence.
1
Refined for your program:
We shape our approach around the needs of each program, not the other way around.
2
Direct access to senior experts:
Our lean model keeps scientific expertise close to the work and communication clear.
3
Built to de-risk progress:
We help you de-risk development through rigorous science and practical support.
4
Protecting data integrity:
Our work is designed to support reliable outputs and maintain confidence in the data.
Why AGADA?
We bring dedicated expertise to programs where there is little room for error, providing the scientific support, responsiveness and program fit that help rare disease teams move forward with clarity.
Decade of specialization:
Founded in 2013 as a spinout from Children’s National Medical Center to provide specialist scientific support for rare disease drug development.
Consistent audit success:
We successfully pass an average of five sponsor audits annually to support clinical trials across multiple phases.
Historical benchmarking:
We leverage archival data from over 100 trials in mouse models of muscular dystrophy to accurately power your efficacy studies.
Dedicated scale:
We operate with a team of approximately 50 employees, entirely focused on executing complex rare disease programs.
Meet more of the leadership team
